However, we found reduced REV1 expression to be correlated with poorer patient prognosis in lung cancer (first progession (FP): HR, 0.42, 95% CI, 0.28–0.61, p = 2.3e-06; OS: HR, 0.53, 95% CI, 0.43–0.65, p = 6.2e-10; PPS: HR, 0.54, 95% CI, 0.34–0.84, p = 0.0055) (Figures 9D–F), Rectum adenocarcinoma (OS: HR, 0.24, 95% CI, 0.08–0.74, p = 0.0084; RFS: HR, 0.08, 95% CI, 0.01–0.99, p = 0.022) (Figures 9G,H) and breast cancer (RFS: HR, 0.77, 95% CI, 0.66–0.89, p = 0.00073) (Figure 9I). This evidence concerns the gene REV1 and lung carcinoma.